Join
Live feed
·
PRReleasevia Quantisnow
Neumora Therapeutics Inc. logo

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

ByQuantisnow·Wall Street's wire, on your screen.
NMRA· Neumora Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NMRA (Neumora Therapeutics Inc.) and more on Quantisnow.